Coya Therapeutics, Inc.
COYA
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candā¦ read more
Healthcare
Biotechnology
2 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$5.49
Price+3.59%
$0.19
1Y
Price
Market Cap
$91.219m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-59.2%
EBITDA Margin-59.4%
Net Profit Margin-31.7%
Free Cash Flow MarginRevenue
$3.988m
+12.2%
1y CAGR-9.5%
3y CAGR-7.1%
5y CAGREarnings
-$18.433m
-23.9%
1y CAGR-25.1%
3y CAGR-56.4%
5y CAGREPS
-$1.11
-13.3%
1y CAGR-0.5%
3y CAGR-16.9%
5y CAGRBook Value
$27.284m
$32.043m
Assets$4.758m
Liabilities-
DebtDebt to Assets
0.0%
-
Debt to EBITDAFree Cash Flow
-$2.838b
-27479.3%
1y CAGR-9175.3%
3y CAGR-6901.3%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company